NKILT Therapeutics: next gen cell therapy to more cancer patients

We will bring a novel off-the-shelf cell therapy to tackle over half of cancers across hematologic and solid tumors. Our unique technology will allow to scale manufacturing so we can "democratize" cell therapy and build new treatments for more patients, globally, and make cell therapy accessible, affordable and down the road profitable.

Our unique proprietary binding technology (with US patent granted in 2Q2025, under fast track globally), called CIR™ (Chimeric ILT-Receptor), brings better outcome in targeting cancer cells and limit the risks of immune escape mechanisms used by cancer cells. It also allows our engineered cells to deliver better outcome vs. standard CAR or antibody-based technologies. Our initial focus is with NK cells, but our CIR™ technology is applicable to all immune cells (T cells, NKT cells, etc...).

In addition, our second IP (under review currently), focused on activation of our cells and enhances significantly their ability to kill cancer cells (making them true serial killers of cancer cells), but also increases persistence of our cells so they can continuously deploy their serial killing ability for up to 6 week.

With such technology, we should be able to bring similar activity,. or even better, than existing anti-body-based technology, and could tackle large cancer population, like colorectal, esophegeal, bladder, breast, etc... and multiple hematologic malignancies.